Whether you're sourcing peptides or other compounded medications, knowing how your products are sourced is just as important as the product itself
Suppress glucagon secretion: Inhibits glucagon release from pancreatic -cells, which reduces hepatic glucose production, which improves glycemic control
Gastrointestinal Side Effects are the predominant category of adverse reactions: Nausea affects approximately 12-24% of diabetes patients and up to 30% of weight management patients, typically most severe during the first few weeks of treatment or following dose increases Diarrhea occurs in 13-17% of diabetes patients and up to 24% of weight management patients Vomiting is reported by 6-10% of diabetes patients and up to 12% of weight management patients, particularly at higher doses Constipation affects 6-11% of diabetes patients and up to 17% of weight management patients Dyspepsia and abdominal pain occur in 6-9% of patients Decreased appetite is common and contributes to the medication's weight loss effects Gastroesophageal reflux disease (GERD) occurs in some patients, particularly at higher doses These gastrointestinal symptoms typically diminish over time as the body adapts to the medication
The starting dose of 0.25 mg is intentionally subtherapeutic
It is a dual-action injectable medication and it has an action that is called twincretin
Patients should also make necessary lifestyle changes, such as regular exercise and a reduced-calorie diet
